Larimar Proposes Another Mid-Stage Study For Rare Neuromuscular Disorder

Larimar Therapeutics Inc LRMR received meeting minutes from the FDA following a recent Type C Meeting.
The company plans to submit a complete response to the CTI-1601 clinical hold in Q3.
In conjunction with the complete response, Larimar is proposing as CTI-1601's next trial a Phase 2, four-week dose exploration study in Friedreich's Ataxia starting at the lower dose levels tested in the company's Phase 1 multiple-ascending dose trial.
This study will provide additional data on safety & tolerability and whether lower doses for longer periods can increase frataxin levels while maintaining acceptable exposures.
Related: FDA Asks For Additional Data To Resolve Clinical Hold On Larimar's Friedreich's Ataxia Program.
Data from Phase 1 trials showed that 50 or 100 mg of CTI-1601, administered daily for at least seven days, resulted in frataxin levels in peripheral tissues (buccal cells).
Cohort 1 of the MAD trial evaluated a 25 mg dose and explored a daily dosing regimen for only four days.
Larimar ended the June quarter with a cash balance of $54.9 million, which provides a projected cash runway through Q3 of 2023.
Price Action: LRMR shares are up 14.64% at $2.27 during the premarket session on the last check Friday.